SUMMARY Eighty two patients with an endoscopically healed gastric ulcer, were treated for two years with either Caved-S tablets, two twice daily or cimetidine 400mg at night. During the first year, 12% (four out of 34) of the Caved-S group and 10% (four out of 41) of the cimetidine group had an ulcer recurrence. By the end of the second year, the recurrence rate was 29% (nine out of 31) in the Caved-S group, and 25% (eight out of 32) for the cimetidine group. Ulcer relapse occurred frequently in patients with either a dyspeptic history of over six months (p<005), or a past history of a gastric ulcer (p<0001). Ulcers recurred rapidly after maintenance therapy; Caved-S two out of 22; cimetidine seven out of 23, within four months (NS). This study shows that long term maintenance therapy is safe and reasonably effective. The high recurrence rate after stopping treatment suggests that therapy in high risk or elderly patients should be for life.
In 1982 we published the results of a comparison between cimetidine and Caved-S in the treatment of gastric ulceration, with the preliminary results of the subsequent two year period of maintenance therapy.1 In this paper we present the final results of that study, and also review the place of such treatment in the prevention of gastric ulcer recurrence.
Methods

PATIENTS
Eighty two patients with healed gastric ulcers were treated for two years with either Caved-S (deglycyrrhizinated liquorice, antacids, and up to 1980 bismuth subcitrate) two tablets twice daily or cimetidine 400mg at night. They were seen as outpatients at three monthly intervals. All patients with a return of symptoms lasting for more than a few days were endoscoped. After six months treatment, a barium meal was carried out. Standard haematological and biochemical screening was undertaken at six monthly intervals. All patients who completed the study were then followed up for a further four months.
The Log-rank test as described by Peto et al2 was used to compare ulcer recurrence in the two groups, and to look for factors influencing it.
Results
The two treatment groups were evenly matched for all important parameters (Table 1 ). The recurrence rate in the two groups was similar (NS see Table 2 ). During the two years treatment, approximately a quarter of the patients relapsed.
The withdrawal rate for the two year treatment periods were similar (Table 3) . One patient with an antral ulcer healed on Caved-S, developed a gastric cancer high on the lesser curve 16 months later. The safety screening programme picked up one patient on cimetidine who developed abnormal liver function tests (SGPT 109) but these returned to normal within two months of stopping treatment.
Within four months of stopping maintenance therapy, nine ulcers recurred, seven in patients who had been on cimetidine, and two in those on Caved-S (NS see Table 2 ).
The duration of ulcer disease, and a past history of gastric ulcer predispose to ulcer recurrence (p<005 and p<0001 respectively). Recurrence is not influenced by initial treatment, sex, age, smok- ing, or drinking habits, ulcer size or site, inpatient treatment at the start of therapy or non-steroidal anti-inflammatory drug therapy.
Discussion
Modern treatment methods will heal the majority of gastric ulcers in two to three months, but ulcer recurrence is known to be rapid once therapy is stopped (30-90% within a year).3-' Unlike duodenal ulcers, gastric ulcers occur mainly in the el- had risen to 29% and 25% respectively. In a previous study we followed a similar group of unselected patients, not on maintenance therapy, for two years and found a recurrence rate of 33% after one year, rising to 44% at the end of two years.
A review of the literature30l shows a one year recurrence rate on maintenance therapy of 0-21% but few studies have continued beyond this ( Table   4 ).
The incidence of asymptomatic ulcer recurrence is unclear. Hentschel and coworkers6 found that 24% of the relapses in their study were asymptomatic. In a recent review of maintenance therapy with ranitidine,"1 only 7% of the ulcer recurrences were asymptomatic. We looked for asymptomatic ulcer recurrence by radiology after six months treatment and found two ulcers. The importance of an ulcer recurrence that produces neither symptoms nor complications is unknown.
This study confirms that two years of maintenance therapy with either Caved-S or cimetidine will reduce symptomatic ulcer recurrence safely and effectively. Patients with a past history of gastric ulceration and dyspeptic symptoms of more than six months duration are more likely to have a recurrence during therapy (p<005 and p<O0OO1 respectively). These patients may require full healing dosage for maintenance therapy to keep them in remission.
How long should maintenance therapy be continued? In an attempt to answer this question, the patients were followed for a further four months after maintenance therapy was stopped. Twenty per cent of these patients developed an ulcer recurrence within this observation period, two out of 22 (9%) in the Caved-S group and seven out of 23 (30%) in the cimetidine group (NS). This rapid gastric ulcer recurrence after stopping maintenance therapy has not been recorded previously although it is well recognised in duodenal ulcer disease. 12
During the four month period, one of the patients (who had previously been on cimetidine), presented with a severe gastrointestinal bleed from a large recurrent ulcer, and died after surgery. Maintenance therapy should perhaps be for life in the elderly or those with multiple pathology, particularly as the standard operation for gastric ulcer is a Bilroth I partial gastrectomy, with its associated mortality and morbidity. 
